Antimicrobial Resistance Patterns of Ventilator-associated Pneumonia in Critically Ill Children

Because the microbiological spectrum and resistance profiles of VAP vary widely based on local hospital ecology and stewardship practices, continuous localized surveillance is mandatory to guide effective empirical therapy.Delineating these patterns is especially urgent in resource-constrained tertiary centers managing high patient volumes.By mapping the specific pathogen distribution and susceptibility profiles within the intensive care unit, this study aims to optimize initial empirical antibiotic selection, inform targeted institutional antimicrobial stewardship, and ultimately reduce the substantial morbidity and mortality associated with pediatric VAP. IntroductIonVentilator-associated pneumonia (VAP) is the second most frequent hospital-acquired infection among critically ill children after urinary tract infection.Defined as nosocomial pneumonia arising ≥48 hours following endotracheal intubation, VAP severely complicates the clinical course of pediatric and neonatal patients by prolonging mechanical ventilation, extending hospitalization, and escalating healthcare costs. 1 Because children present fundamental differences in airway anatomy, respiratory physiology, and immune maturation, pediatric VAP management cannot simply be extrapolated from adult data. 2 Although diagnostic criteria have transitioned toward objective surveillance frameworks like the Centers for Disease Control and Prevention's (CDC's) Ventilator-Associated Events (VAE) algorithm, 3 VAP remains a pervasive challenge in pediatric and neonatal intensive care units globally, with reported incidences spanning 2-17%. 2 Pathogenesis typically involves the direct lower airway inoculation of colonized aerodigestive flora or contaminated secretions.Predisposing risk factors span host-related (e.g., prematurity, immunosuppression), device-related, and personnel-related determinants.4 Common etiological agents include Pseudomonas spp., Staphylococcus aureus, Klebsiella pneumoniae, and Acinetobacter baumannii.5 Crucially, recent surveillance highlights an alarming global rise in multidrug-resistant (MDR) Gram-negative bacilli, directly driving treatment failures and mortality.